GlassScriptPhysician profile
Randall N Stein
NPI 1376807214
$7,422.10
in general payments reported to CMS, 2019-2025
27 companies · $1,196 in 2025
The $1,196 reported for 2025 was more than what 81% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,030 · 2020: $636 · 2021: $381 · 2022: $1,692 · 2023: $1,006 · 2024: $1,482 · 2025: $1,196.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,683.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,683.38 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $3,154.58 | 2019-2025 | Hydrus Microstent, Ngenuity, Rocklatan |
| Aerie Pharmaceuticals, INC. | $580.80 | 2019-2021 | |
| Allergan, INC. | $441.82 | 2019-2022 | |
| Abbvie INC. | $418.17 | 2022-2025 | Durysta |
| New World Medical,INC. | $386.16 | 2019-2025 | Clearpath, Streamline, Kahook Dual Blade |
| US Retina LLC | $358.42 | 2022 | |
| Ivantis, INC | $316.84 | 2019-2021 | |
| Johnson & Johnson Surgical Vision, INC. | $272.26 | 2019-2024 | Tecnis Iol, Tecnis Iol |
| Tarsus Pharmaceuticals, INC. | $269.04 | 2024-2025 | Xdemvy |
| Kala Pharmaceuticals, INC. | $265.73 | 2019-2021 | |
| Bausch & Lomb Americas INC. | $177.84 | 2022-2024 | Vyzulta |
| Horizon Therapeutics Plc | $175.06 | 2023 | Tepezza |
| Sight Sciences, INC. | $113.45 | 2022-2024 | Omni Surgical System |
| Sun Pharmaceutical Industries INC. | $65.55 | 2019-2023 | Cequa, Xelpros |
| Glaukos Corporation | $63.26 | 2023-2025 | Idosetr, Istent Trabecular Micro-Bypass System Model Is3 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $53.54 | 2022-2023 | |
| Oyster Point Pharma, INC. | $50.85 | 2024-2025 | Tyrvaya, Ryzumvi, Ryzumvi |
| Rayner Intraocular Lenses Limited | $40.61 | 2025 | Omidria |
| Harrow Eye, LLC | $33.45 | 2025 | Vevye |
| Iridex Corporation | $30.41 | 2019-2023 | |
| Amgen INC. | $29.92 | 2025 | Tepezza |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $29.78 | 2019 | |
| Thea Pharma INC. | $28.55 | 2025 | Iyuzeh |
| Dompe US, INC. | $18.91 | 2025 | Oxervate |
| Eyepoint US, INC. | $17.51 | 2019 | |
| Shire North American Group INC | $17.41 | 2019 | |
| Topcon Healthcare, INC. | $12.18 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$13,674.10 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Randall Stein listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.